Compare Genedata Biologics vs. Recursion

Genedata Biologics® enhances the development of biotherapeutics, including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs, providing a comprehensive solution for the industry. Recognized as the leading platform in the field, it seamlessly unifies all discovery workflows, allowing researchers to prioritize genuine innovation. By utilizing a pioneering platform that was purposefully created to digitalize the biotherapeutic discovery process, research can be accelerated significantly. The platform simplifies intricate R&D tasks by facilitating the design, tracking, testing, and evaluation of novel biotherapeutic drugs. It is compatible with various formats, such as antibodies, bi- or multi-specifics, ADCs, innovative scaffolds, and therapeutic proteins, as well as engineered therapeutic cell lines like TCRs and CAR-T cells. Functioning as a comprehensive end-to-end data backbone, Genedata Biologics connects all R&D processes, including library design, immunization, selection and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, ultimately leading to thorough assessments of candidate developability and manufacturability. This holistic integration ensures that researchers can make informed decisions and push the boundaries of biotherapeutic innovation effectively.

We are a biotechnology firm in the clinical stage, dedicated to unraveling biological complexities through the integration of cutting-edge innovations spanning biology, chemistry, automation, machine learning, and engineering, all aimed at revolutionizing drug discovery. Our approach allows for enhanced precision in biological manipulation with advanced techniques like CRISPR genome editing and synthetic biology. We also achieve reliable automation for intricate laboratory processes at an unprecedented scale through the use of sophisticated robotics. By employing neural network architectures, we conduct iterative analyses and draw insights from extensive, intricate datasets generated in-house. Furthermore, we are boosting the adaptability of high-performance computing capabilities through cloud-based solutions. Our initiative harnesses new technologies to foster continuous learning cycles around our datasets, establishing us as a next-generation biopharmaceutical enterprise. This is achieved through a harmonious integration of hardware, software, and data, all dedicated to the industrialization of drug discovery. We are transforming the conventional drug discovery pipeline and boast one of the most extensive, diverse, and in-depth pipelines among technology-driven drug discovery companies. Ultimately, our mission is to enhance the efficiency and effectiveness of drug development, paving the way for breakthrough therapies.